在性结肠炎治疗中酸作为多稳定剂用于增强miR-124输送的查
Mingju Shui1, Yi Chen1, Miao Guo2
1State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China; Macao Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China.
这项研究开发了一种新型纳米载体,使用西纳皮酸进行有效的miRNA输送,以治疗性结肠炎 (UC). 在小鼠模型中,治疗减少了炎症并改善了肠道健康,为UC提供了新的治疗策略.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 具有有限的治疗选择,并具有显著的副作用.
- 目前的核酸输送系统在有效性和多优化方面面临着挑战.
研究的目的:
- 系统地选天然多,以开发有效的miRNA输送系统,用于UC.
- 在UC治疗中创建一个基于多的纳米载体,用于针对性miRNA输送.
主要方法:
- 对110种天然多醇进行系统选,以确定最佳候选物.
- 开发一种氨酸 (HA) 涂层的多胺胺胺 (PAMAM) 树突分子纳米载体 (HPPR NPs) 封装酸 (SA) 和miR-124模仿剂.
- 在硫酸德克斯 (DSS) 诱导的急性结肠炎小鼠模型中的评估.
主要成果:
- 酸 (SA) 被确定为开发HPPRNP的主要多.
- HPPR NPs促进了miR-124的有效细胞内传递,降低了关键的炎症标 (IL-6R,CCL-2,STAT3).
- 该纳米载体抑制了促炎性细胞因子,促进了粘膜再生,并恢复了肠道微生物群的稳定性.
结论:
- 建立了一个基于多的策略,以优化核酸输送.
- 开发的纳米治疗平台对有效的性结肠炎治疗有显著的前景.
更多相关视频
08:34Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
